Skip to content
value.today

Alimera Sciences: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value

The newest statements on file are more than two years old.

Your own DCF model

A full discounted-cash-flow model of Alimera Sciences, started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against its own history

Alimera Sciences's multiples at each month end with a market cap on file, Jan 2020 to Jan 2024, each against its own median.

Price to sales

3.9×

Now above its median of 0.6×, in the top quarter of its range; range 0.3× to 3.9× over 6 months.

0×1×2×3×4×20202021202220232024Price to sales 4×Median 1×

As of Jan 5, 2024

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2023to Dec 31, 2023$81 M$-20 M$-14 M$0 M$-15 M—SEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$54 M$-18 M$-10 M$0 M$-10 M—SEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$59 M$-4 M$-3 M$1 M$-4 M—SEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$51 M$-5 M$-2 M$1 M$-3 M—SEC annual report (10-K, 20-F)
FY2019to Dec 31, 2019$54 M$-10 M$-4 M$0 M$-4 M$33 MSEC annual report (10-K, 20-F)
FY2018to Dec 31, 2018$47 M$-16 M$-12 M$0 M$-12 M$27 MSEC annual report (10-K, 20-F)